



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
PTO - 1449 FORM**

**ATTY. DOCKET NO.**  
11245/48503

**SERIAL NO.**  
10/520,026

**APPLICANT**  
ZHU, Zhenping

**FILING DATE**  
December 27, 2004

**GROUP**

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
/P.H./	6,383484	May 7, 2002	Achen et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/P.H./	WO 95/009917	April 13, 1995	PCT				

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.	
/P.H./	Yang et al., CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anit-HIV-1 Antibody into the Picomolar Range. J. Mol. Biol. 1995, vol. 254, pages 392-403	
/P.H./	Kortt et al., Single-chain Fv Fragments of Anit-neuraminidase Antibody NC10 containing Five-and ten-residue linkers Form Dimers and with Zero-residue Linker a Trimer. Protein Engineering 1997, Vol. 10, No. 4, pages 423-425	
/P.H./	Lu, D. Complete Inhibition of Vascular Endothelial Growth Factor (VEGF) Activities with a Bifunctional Diabody Directed against Both VEGF Kinase Receptors, fms-like Tyrosine Kinase Receptor Cancer Research October 2001, Vol. 61. pages 7002-7008	
/P.H./	Lu, D. Acquired Antagonistic Activity of a Bispecific Diabody Directed Against Tow Different Epitopes in Vascular Endothelial Growth Factor Receptor 2 J. Immunol. Methods November 1999, Vol. 230. No. 1-2, pages 159-171	

<b>EXAMINER</b> /Phuong Huynh/	<b>DATE CONSIDERED</b> 06/11/2009
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	